CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important.

Overview
Identity
Additional Document Info
View All

authors

David M. Holtzman, MD

publication date

January 1, 2012

published in

Archives of neurology Journal

has subject area